It was reported on November 22 that the combination of new crown drugs brii-196 and brii-198, jointly developed by Tsinghua University, Shenzhen Third People's Hospital and tengshengbo pharmaceutical, has obvious advantages in the global research and development of new crown specific drugs. According to the latest news obtained by the reporter, the clinical phase III of the "seed drug" has been unblinded. The administration group achieved zero death after 28 days of treatment, and 8 cases in the control group died. The detailed results will be announced in the near future. (Xinhua News Agency)